Informazione Regolamentata n. 20349-33-2026	Data/Ora Inizio Diffusione 3 Novembre 2026 18:44:03	Euronext Growth Milan

Societa'	:	PIU’ MEDICAL
Utenza - referente	:	PIUMEDICALESTN01 - Giordano Fabio
Tipologia	:	2.2
Data/Ora Ricezione	:	3 Novembre 2026 18:44:03
Data/Ora Inizio Diffusione	:	3 Novembre 2026 18:44:03
Oggetto	:	PIÙ MEDICAL: COMPLETION OF THE ACQUISITION OF 60% OF FARMACIA DELL'AQUILA IN GENOA

Testo del comunicato

Vedi allegato

Teleborsa: distribution and commercial use strictly prohibited

PIÙ MEDICAL: COMPLETION OF THE ACQUISITION OF 60% OF FARMACIA DELL'AQUILA IN GENOA

Castronno (VA), November 03, 2026 – **Più Medical S.p.A.** ("**Più Medical**," the "**Company**"), a company whose shares are traded on Euronext Growth Milan and which is active in the development and management of pharmacies and integrated healthcare services, following the press release issued on August 5, 2026, announces that the closing of the transaction to acquire 60% of the share capital of Farmacia dell'Aquila S.r.l. (the "**Transaction**" and "**Farmacia dell'Aquila**" respectively) has been completed today.

The Transaction represents **the second acquisition completed by the Company since its stock market listing**, and its finalization is part of the growth strategy through selective acquisitions already implemented; expands the Group's expertise and increases its presence in Northern Italy. Commercial know-how will be progressively transferred within the Group, also thanks to the continued operational involvement of the selling shareholders, who will retain a 40% stake.

Farmacia dell'Aquila, one of historic pharmacies in Genoa's San Fruttuoso neighborhood, reported total revenues of approximately €14.5 million in 2025, total EBITDA[1] of approximately €0.5 million, and net financial debt of approximately €1.1 million. The pharmacy retail and aesthetic medicine businesses marketed in Italy, which represent the strategic rationale for the Transaction, generated combined revenues of €3.3 million in 2025, with an overall margin of approximately 15% on the related revenues.
The estimated amount, totaling approximately €3.0 million, is to be paid in several tranches using funds available to the Company. As of today, pursuant to the binding agreement, Più Medical paid the sellers an amount of approximately €1.7 million, in addition to the advance payment of €0.3 million already made upon execution of the agreement. A deferred payment of approximately €1.0 million is also envisaged, subject to the price adjustment mechanism provided for in the binding agreement, with the final amount to be determined by the end of fiscal year 2026. A potential earn-out is also expected, calculated on the basis of the performance of revenues attributable to the aesthetic medicine product line distributed in Italy during the twelve months following the closing of the Transaction; if due, it will be paid upon fulfillment of the margin conditions set forth in the binding agreement.

A portion of the Payment, amounting to €100,000, will be reinvested by the selling shareholders in Più Medical ordinary shares through a capital accumulation plan (PAC), aimed at fostering their involvement in the Group's long-term value creation. The PAC will be launched following completion of the closing; the shares purchased under the plan will be subject to a twelve-month lock-up period beginning on the date of the last purchase made under the plan.
The binding agreement also provides for the potential acquisition by Più Medical of the remaining 40% of Farmacia dell'Aquila's share capital through a put and call option mechanism.

For further information regarding the Transaction, the determination of the payment and its additional terms, please refer to the press release dated August 5, 2026.

[1] Total EBITDA calculated based on 2025 data prepared in accordance with IFRS for the purposes of the Transaction.

Teleborsa: distribution and commercial use strictly prohibited

Finally, please note that the Transaction qualifies as a significant transaction pursuant to Article 12 of the Euronext Growth Milan Issuers' Regulations.

***

This press release is available in the Investor Relations / Press Releases section of the website https://piumedical.com/ and on www.emarketstorage.it.

For the dissemination of regulated information, Più Medical uses the eMarket SDIR network (www.emarketstorage.it , managed by Teleborsa S.r.l., headquartered at Piazza di Priscilla, 4, Rome.

***

CONTACTS

Investor Relator
Fabio Luigi Giordano
Viale Lombardia 62, 21040 Castronno (VA)
+39 0332 896059
investor@piumedical.com

Euronext Growth Advisor & Specialist
Banca Investis S.p.A.
Via Broletto, 5, 20121 Milano
+ 39 0299968127
marco.pelosi@bancainvestis.com

Media Relations
Twister Communications Group
Via Valparaiso, 3 - 20144 Milano
Tel. +39 02438114200
piumedical@twistergroup.it

The Company
Più Medical, founded in 2025 and whose shares are traded on Euronext Growth Milan, currently operates a network of 17 pharmacies and pursues a growth strategy based on the acquisition, integration and development of local pharmacies, alongside the progressive expansion of complementary healthcare services and capabilities. The operating model integrates industrial, managerial, and commercial expertise, leveraging structured processes, economies of scale, and a governance structure capable of supporting future growth.

Teleborsa: distribution and commercial use strictly prohibited

Fine Comunicato n.20349-33-2026	Numero di Pagine: 5